A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Rinella, Mary E.; Lazarus, Jeffrey V.; Ratziu, Vlad; Francque, Sven; Sanyal, Arun J.; Kanwal, Fasiha; Romero, Diana Fernández; Abdelmalek, Manal F.; Anstee, Quentin M.; Arab, Juan Pablo; Arrese, Marco; Bataller, Ramón; Beuers, Ulrich; Boursier, Jérôme; Bugianesi, Elisabetta; Byrne, Christopher D.; Narro, Graciela Elia Castro; Chowdhury, Abhijit; Cortez‐Pinto, Helena; Cryer, Donna; Cusi, Kenneth; Kassas, Mohamed El; Klein, Samuel; Eskridge, Wayne; Fan, Jian‐Gao; Gawrieh, Samer; Guy, Cynthia D.; Harrison, Stephen A.; Kim, Seung Up; Koot, Bart; Korenjak, Marko; Kowdley, Kris V.; Lacaille, Florence; Loomba, Rohit; Mitchell-Thain, Robert; Morgan, Timothy R.; Powell, Elisabeth; Roden, Michael; Romero‐Gómez, Manuel; Silva, Marcelo; Singh, Shivaram Prasad; Sookoian, Silvia; Spearman, C Wendy; Tiniakos, Dina; Valenti, Luca; Vos, Miriam B.; Wong, Vincent Wai‐Sun; Xanthakos, Stavra A.; Yılmaz, Yusuf; Younossi, Zobair M.; Hobbs, A; Villota-Rivas, Marcela; Newsome, Philip N.

doi:10.1016/j.aohep.2023.101133

Cited by 204 publications

(175 citation statements)

References 31 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…Recurrent steatosis is nearly universal in patients transplanted for MASLD and commonly occurs as de novo MASLD in those with other indications for transplant; 61,62 however, progression to advanced fibrosis from recurrent MASH is rare. 63 Overall survival of patients transplanted for MASH is similar to those transplanted for other indications, 64,61 and those with recurrent steatosis have 5-year survival rates on par with patients without recurrence. 62 However, a recent study found that patients transplanted for MASH at ≥65 years-old or those with diabetes have worse survival than their counterparts, 65 and similar to the non-LT population, 66 cardio-vascular events were common causes of mortality.…”

Section: Metabolic Dysfunction-associated Steatohepatitis (Mash)mentioning

confidence: 76%

Evolving challenges with long‐term care of liver transplant recipients

Odenwald,

Roth,

Reticker

et al. 2023

Clinical Transplantation

View full text Add to dashboard Cite

The number of liver transplants (LT) performed worldwide continues to rise, and LT recipients are living longer post‐transplant. This has led to an increasing number of LT recipients requiring lifelong care. Optimal care post‐LT requires careful attention to both the allograft and systemic issues that are more common after organ transplantation. Common causes of allograft dysfunction include rejection, biliary complications, and primary disease recurrence. While immunosuppression prevents rejection and reduces incidences of some primary disease recurrence, it has detrimental systemic effects. Most commonly, these include increased incidences of metabolic syndrome, various malignancies, and infections. Therefore, it is of utmost importance to optimize immunosuppression regimens to prevent allograft dysfunction while also decreasing the risk of systemic complications. Institutional protocols to screen for systemic disease and heightened clinical suspicion also play an important role in providing optimal long‐term post‐LT care. In this review, we discuss these common complications of LT as well as unique considerations when caring for LT recipients in the years after transplant.

show abstract

Section: Metabolic Dysfunction-associated Steatohepatitis (Mash)mentioning

confidence: 76%

Evolving challenges with long‐term care of liver transplant recipients

Odenwald,

Roth,

Reticker

et al. 2023

Clinical Transplantation

View full text Add to dashboard Cite

show abstract

“…All patients met the criteria for MASLD. [30][31][32] Patients were prescribed pemafibrate (oral, 0.1 mg, twice a day) and instructed to visit the outpatient clinic every 4-12 weeks. The Common Terminology Criteria for Adverse Events version 5.0 was used to evaluate the adverse events associated with pemafibrate.…”

Section: Methodsmentioning

confidence: 99%

“…The new nomenclature is nonstigmatizing and can improve awareness and patient identification. [30][31][32] In this study, we have evaluated the effects of pemafibrate in patients with MASLD and hypertriglyceridemia, focusing on liver enzymes and the utilization of MRI-based noninvasive tests.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the effects of pemafibrate on metabolic dysfunction‐associated steatotic liver disease with hypertriglyceridemia using magnetic resonance elastography combined with fibrosis‐4 index and the magnetic resonance imaging‐aspartate aminotransferase score

Ichikawa,

Oba,

Owada

et al. 2023

JGH Open

View full text Add to dashboard Cite

Background and AimIn this retrospective study, we evaluated the effects of pemafibrate treatment in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) and hypertriglyceridemia using non‐invasive stiffness‐based models, including magnetic resonance elastography (MRE) combined with the fibrosis‐4 (FIB‐4) (MEFIB) index and the magnetic resonance imaging (MRI)‐aspartate aminotransferase (AST) (MAST) score.MethodsIn total, 179 patients with MASLD treated with pemafibrate were enrolled. We evaluated the effects of 48‐week pemafibrate treatment using the MEFIB index, which classifies patients based on the combination of liver stiffness measurement (LSM) on MRE and FIB‐4 and the MAST score, which is calculated based on LSM on MRE, MRI‐proton density fat fraction (MRI‐PDFF), and AST levels.ResultsPemafibrate treatment led to significant reduction in AST, alanine aminotransferase (ALT), and gamma‐glutamyl transferase (GGT) (P = 0.011, <0.001, and <0.001, respectively) and significant improvements in triglyceride and high‐density lipoprotein cholesterol levels (P < 0.001 and <0.001, respectively). The MRI‐PDFF values were not significantly altered. However, a significant decrease in LSM on MRE was detected (P = 0.003). Evaluation of fibrosis using the MEFIB index and MAST score demonstrated significant improvement (P = 0.004 and <0.001, respectively). Changes in the MAST score showed positive correlation with changes in ALT and GGT levels (r = 0.821, P < 0.001, and r = 0.808, P < 0.001, respectively). Additionally, ALT and GGT levels at baseline were significantly associated with improvements in the MAST score (P < 0.001 and <0.001, respectively).ConclusionPemafibrate led to improvements in the MEFIB index and MAST score, as well as liver function. It is a promising therapeutic agent for patients with MASLD and hypertriglyceridemia with the potential to reduce liver‐related events.

show abstract

“…Die Inzidenz maligner Lebertumore hat in den vergangenen Jahrzehnten kontinuierlich zugenommen. Das primäre Leberzellkarzinom (HCC) ist hierbei der weltweit häufigste maligne Lebertumor, in der westlichen Welt vor allem aufgrund chronischer HCV-Infektion-bedingter oder alkoholbedingter Leberzirrhosen und der Zunahme der mit einer metabolischen Dysfunktion assoziierten Fettleber-Erkrankungen (MASLD), mit fortgeschrittener Fibrose oder Zirrhose [7,8]. Aus diesem Grund empfehlen die verschiedenen Fachgesellschaften Patienten mit erhöhtem HCC-Risiko die Teilnahme an einem Früherkennungsprogramm, basierend auf halbjährlichen Ultraschall-Untersuchungen der Leber [8,9].…”

Section: Ki Zur Früherkennung Und Charakterisierung Fokaler Leberläsi...unclassified

Ultrasound Diagnosis of Hepatocellular Carcinoma: Is the Future Defined by Artificial Intelligence?

Waldner,

Strobel

2024

Ultraschall Med

View full text Add to dashboard Cite

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Cited by 204 publications

References 31 publications

Evolving challenges with long‐term care of liver transplant recipients

Evolving challenges with long‐term care of liver transplant recipients

Evaluation of the effects of pemafibrate on metabolic dysfunction‐associated steatotic liver disease with hypertriglyceridemia using magnetic resonance elastography combined with fibrosis‐4 index and the magnetic resonance imaging‐aspartate aminotransferase score

Ultrasound Diagnosis of Hepatocellular Carcinoma: Is the Future Defined by Artificial Intelligence?

Contact Info

Product

Resources

About